ArticleNeurochemical research2025
HAT1 Protects Against Cerebral Ischemia Injury by Inhibiting TFRC-Mediated Ferroptosis.
Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Molecular Mechanism of LncRNA LUCAT1 Regulating HSPB8 Expression via miR-337-3p in Modulating Neurological Damage After Cerebral Infarction.Neurochemical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ferroptosis is a pathogenesis of stroke. Succinylation is a promising therapeutic target for stroke. This study aimed to investigate the impact of succinyltransferase HAT1 in the progression of ischemic stroke and the underlying mechanism. HT-22 cells were stimulated by oxygen glucose deprivation to induce cell death. Mice received middle cerebral artery occlusion (MCAO) to generate a model. Ferroptosis was evaluated using propidium iodide staining and by measuring key indicators, including glutathione (GSH) levels, intracellular Fe²⁺ concentration, reactive oxygen species (ROS) levels, and ferroptosis-related protein levels. Brain infarction was observed using 2,3,5-Triphenyltetrazolium staining. The succinylation of transferrin receptor (TFRC) was measured using immunoprecipitation and western blotting. The results showed that HAT1 expression was downregulated in OGD-related HT-22 cell ferroptosis. Overexpression of HAT1 promoted the viability, as well as inhibited inflammatory response and ferroptosis of OGD-induced cells. Moreover, HAT1 ameliorated neurological dysfunction, brain infarction, and ferroptosis in the brain of MCAO mice. Additionally, we identified a novel mechanism whereby HAT1 interacted with TFRC and promoted its succinylation at K384 and K626 sites, establishing a previously unrecognized post-translational regulatory axis. Overexpression of TFRC or mutants of TFRC at succinylation sites abrogated the effect on cell phenotype induced by HAT1. In conclusion, HAT1 suppresses ferroptosis by promoting TFRC succinylation, thereby attenuating ischemic brain injury. These findings provide a potential therapeutic target for ischemic stroke.
Indexed as
Identifiers
41460540What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.